Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence D Mayer

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Biochimica Et Biophysica Acta|May 9, 2002
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomesNancy Dos Santos, Lawrence D Mayer, Sheela A Abraham, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Molecular Cancer Therapeutics|August 13, 2009
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoPaul G Tardi, Nancy Dos Santos, Troy O Harasym, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancerCorrie Lynn Messerer, Euan C Ramsay, Dawn Waterhouse, et al.
Leukemia Research|February 9, 2010
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenograftsWah-Seng Lim, Paul G Tardi, Nancy Dos Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
Molecular Cancer Therapeutics|August 8, 2006
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing miceLawrence D Mayer, Troy O Harasym, Paul G Tardi, et al.
Biochimica Et Biophysica Acta|February 18, 2004
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanolNancy Dos Santos, Kelly A Cox, Cheryl A McKenzie, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 25, 2006
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserineMurray S Webb, Sharon Johnstone, Tara J Morris, et al.
Pharmaceutical Research|March 6, 2008
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomesAwa Dicko, April A Frazier, Barry D Liboiron, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Biochimica Et Biophysica Acta|May 9, 2002
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomesNancy Dos Santos, Lawrence D Mayer, Sheela A Abraham, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Molecular Cancer Therapeutics|August 13, 2009
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivoPaul G Tardi, Nancy Dos Santos, Troy O Harasym, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancerCorrie Lynn Messerer, Euan C Ramsay, Dawn Waterhouse, et al.
Leukemia Research|February 9, 2010
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenograftsWah-Seng Lim, Paul G Tardi, Nancy Dos Santos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumorsGerald Batist, Karen A Gelmon, Kim N Chi, et al.
Molecular Cancer Therapeutics|August 8, 2006
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing miceLawrence D Mayer, Troy O Harasym, Paul G Tardi, et al.
Biochimica Et Biophysica Acta|February 18, 2004
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanolNancy Dos Santos, Kelly A Cox, Cheryl A McKenzie, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 25, 2006
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserineMurray S Webb, Sharon Johnstone, Tara J Morris, et al.
Pharmaceutical Research|March 6, 2008
Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomesAwa Dicko, April A Frazier, Barry D Liboiron, et al.
Pageof 6